AU2019253028B2 - A2-73 crystalline polymorph compositions of matter and methods of use thereof - Google Patents
A2-73 crystalline polymorph compositions of matter and methods of use thereof Download PDFInfo
- Publication number
- AU2019253028B2 AU2019253028B2 AU2019253028A AU2019253028A AU2019253028B2 AU 2019253028 B2 AU2019253028 B2 AU 2019253028B2 AU 2019253028 A AU2019253028 A AU 2019253028A AU 2019253028 A AU2019253028 A AU 2019253028A AU 2019253028 B2 AU2019253028 B2 AU 2019253028B2
- Authority
- AU
- Australia
- Prior art keywords
- anavex2
- xrpd pattern
- freebase
- crystalline
- rule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Furan Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024205423A AU2024205423B2 (en) | 2018-04-12 | 2024-08-02 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862656435P | 2018-04-12 | 2018-04-12 | |
| US62/656,435 | 2018-04-12 | ||
| PCT/US2019/027369 WO2019200345A1 (en) | 2018-04-12 | 2019-04-12 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024205423A Division AU2024205423B2 (en) | 2018-04-12 | 2024-08-02 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019253028A1 AU2019253028A1 (en) | 2020-10-15 |
| AU2019253028B2 true AU2019253028B2 (en) | 2024-05-30 |
Family
ID=68163817
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019253028A Active AU2019253028B2 (en) | 2018-04-12 | 2019-04-12 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
| AU2024205423A Active AU2024205423B2 (en) | 2018-04-12 | 2024-08-02 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024205423A Active AU2024205423B2 (en) | 2018-04-12 | 2024-08-02 | A2-73 crystalline polymorph compositions of matter and methods of use thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11498908B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3773531A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP7532718B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112105349A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2019253028B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3096671C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019200345A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
| WO2021158586A1 (en) | 2020-02-04 | 2021-08-12 | Teva Pharmaceuticals International Gmbh | Solid state forms of blarcamesine salts |
| JP2025514292A (ja) * | 2022-04-29 | 2025-05-02 | ▲蘇▼州科睿思制▲葯▼有限公司 | 塩酸ブラルカメシンの結晶形、その調製方法およびその使用 |
| US12018005B1 (en) | 2023-07-25 | 2024-06-25 | Egis Gyógyszergyár Zrt. | Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030983A1 (en) * | 1996-02-21 | 1997-08-28 | Alexandre Vamvakides | Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts |
| WO2017013498A2 (en) * | 2015-07-22 | 2017-01-26 | Anavex Life Sciences Corp. | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011267474B2 (en) * | 2010-06-15 | 2016-05-26 | Grünenthal GmbH | Pharmaceutical combination for the treatment of pain |
| WO2014159814A1 (en) * | 2013-03-13 | 2014-10-02 | Patricia Oliver | Formulations and tablets for treatment or prevention of neurological disorders |
| GR1008233B (el) * | 2013-03-28 | 2014-06-23 | Αλεξανδρος Δημητριου Βαμβακιδης | Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες |
| AU2016248376B2 (en) * | 2015-04-15 | 2020-10-08 | Beone Medicines I Gmbh | Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore |
| MX388953B (es) * | 2015-05-20 | 2025-03-20 | Ube Industries | Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo. |
| US11617734B2 (en) * | 2015-07-22 | 2023-04-04 | Anavex Life Sciences Corp. | Enantiomers of A2-73, analogues, and sigma agonist activity |
| JP6866379B2 (ja) * | 2016-01-26 | 2021-04-28 | アナベックス ライフ サイエンシズ コーポレイション | 神経発達障害療法 |
| WO2017172784A1 (en) * | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| CN111315375A (zh) * | 2017-06-14 | 2020-06-19 | 阿纳韦克斯生命科学公司 | 用于治疗阿尔茨海默病的anavex2-73 |
| AU2018375667B2 (en) * | 2017-11-28 | 2023-03-02 | Anavex Life Sciences Corp. | Sigma-1 receptor agonist systolic blood pressure therapy |
| CN112105349A (zh) * | 2018-04-12 | 2020-12-18 | 阿纳韦克斯生命科学公司 | A2-73结晶多晶型物质组合物及其使用方法 |
-
2019
- 2019-04-12 CN CN201980031851.3A patent/CN112105349A/zh active Pending
- 2019-04-12 CA CA3096671A patent/CA3096671C/en active Active
- 2019-04-12 CA CA3256071A patent/CA3256071A1/en active Pending
- 2019-04-12 EP EP19785595.0A patent/EP3773531A4/en active Pending
- 2019-04-12 US US17/046,929 patent/US11498908B2/en active Active
- 2019-04-12 WO PCT/US2019/027369 patent/WO2019200345A1/en not_active Ceased
- 2019-04-12 JP JP2020555811A patent/JP7532718B2/ja active Active
- 2019-04-12 AU AU2019253028A patent/AU2019253028B2/en active Active
-
2022
- 2022-11-01 US US17/978,818 patent/US12180174B2/en active Active
-
2024
- 2024-02-05 JP JP2024016033A patent/JP7758768B2/ja active Active
- 2024-08-02 AU AU2024205423A patent/AU2024205423B2/en active Active
- 2024-12-17 US US18/984,748 patent/US20250115566A1/en active Pending
-
2025
- 2025-06-23 JP JP2025105737A patent/JP2025131907A/ja active Pending
- 2025-10-09 JP JP2025171096A patent/JP2026004574A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997030983A1 (en) * | 1996-02-21 | 1997-08-28 | Alexandre Vamvakides | Tetrahydro-n,n-dimethyl-2,2-diphenyl-3-feranemethanamine, its enantiomers, and their pharmaceutically acceptable acid addition salts |
| WO2017013498A2 (en) * | 2015-07-22 | 2017-01-26 | Anavex Life Sciences Corp. | Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions |
Non-Patent Citations (1)
| Title |
|---|
| FOSCOLOS, G. B. ET AL., "Synthesis and pharmacological study of some new β-(dialkylaminomethyl)-γ-butyrolactones and their tetrahydrofuran analogs", Farmaco, 1996, Vol. 51(1), pages19-26 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021521188A (ja) | 2021-08-26 |
| AU2024205423B2 (en) | 2026-06-25 |
| JP2025131907A (ja) | 2025-09-09 |
| US20230142424A1 (en) | 2023-05-11 |
| US11498908B2 (en) | 2022-11-15 |
| JP7532718B2 (ja) | 2024-08-14 |
| EP3773531A4 (en) | 2021-06-23 |
| AU2019253028A1 (en) | 2020-10-15 |
| CA3256071A1 (en) | 2025-10-31 |
| US12180174B2 (en) | 2024-12-31 |
| AU2024205423A1 (en) | 2024-08-22 |
| US20250115566A1 (en) | 2025-04-10 |
| JP2024038524A (ja) | 2024-03-19 |
| JP7758768B2 (ja) | 2025-10-22 |
| EP3773531A1 (en) | 2021-02-17 |
| US20210115004A1 (en) | 2021-04-22 |
| JP2026004574A (ja) | 2026-01-14 |
| CA3096671A1 (en) | 2019-10-17 |
| WO2019200345A1 (en) | 2019-10-17 |
| CN112105349A (zh) | 2020-12-18 |
| CA3096671C (en) | 2025-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12180174B2 (en) | A2-73 crystalline polymorph compositions of matter and methods of use thereof | |
| AU2017213475B2 (en) | SecA inhibitors and methods of making and using thereof | |
| EP2753613B1 (en) | Derivatives of xanthone compounds | |
| EP3365323B1 (en) | Salts of tetracyclines | |
| EP3393457A1 (en) | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant | |
| CA3086611C (en) | A crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof | |
| WO2019196955A1 (zh) | R 10与r 11连接的亲水性小檗碱型衍生物及其制备药物的应用 | |
| EA019689B1 (ru) | Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения | |
| US8471044B2 (en) | Epigallocatechin-3-gallate crystal compositions | |
| CN110035745A (zh) | 小分子ampk活化剂 | |
| CN100445288C (zh) | 银杏内酯b衍生物及其在制药中的应用 | |
| US12098134B2 (en) | Benzo-heterocyclic compound and composition for preventing or treating cancer disease, containing same as active ingredient | |
| AU2022339672B2 (en) | Glun2b-subunit selective antagonists of the n-methyl-d-aspartate receptors with enhanced potency at acidic ph | |
| KR101714259B1 (ko) | 알츠하이머성 치매 예방 또는 치료용 약제학적 조성물(2) | |
| US9776989B2 (en) | Chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders | |
| KR102509190B1 (ko) | 트리메부틴 말레산염의 다형체 및 이의 사용방법 | |
| KR20180124428A (ko) | 결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| KR20180124400A (ko) | 사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
| CN119997948A (zh) | 用于预防退行性疾病引起的认知下降的组合物和方法 | |
| KR20160146428A (ko) | 솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법 | |
| KR20110126132A (ko) | 4,6-디클로로-1η-인돌-2-카르복실산 유도체 또는 이의 염을 유효 성분으로서 함유하는 시신경 장애의 예방 또는 치료제 | |
| WO2019120111A1 (zh) | 二甲双胍盐在治疗脑梗死中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MISSLING, CHRISTOPHER U. AND SELVEY, ALANI |
|
| FGA | Letters patent sealed or granted (standard patent) |